Doctors 'cautiously optimistic' about experimental Alzheimer's drug

Brain scan.
(Image credit: iStock.)

An experimental Alzheimer's drug far outperformed placebo treatments in slowing the cognitive decline of Alzheimer's patients, Stat reported Wednesday, giving neurologists hope that an effective treatment for the disease is possible.

Patients who were given the drug, called BAN2401 and produced by Biogen and Eisai, "performed 30 percent better on a cognitive test than those getting placebo," Stat explained. The positive early returns may move the companies to approach the FDA for approval before conducting a larger study. But "there are caveats," Stat wrote: The drug's Phase 2 trial showed that the drug only outperformed placebo at its highest dose, and the highest dose was administered to just 161 patients. Moreover, the way Biogen and Eisai measured the drug's effectiveness is a proprietary method that has never been presented to the FDA before in an attempt to win approval.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Kimberly Alters

Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.